A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Phase 3
18+
29 sites in AR, CA, FL +15
About this study
This Phase 3 study is testing Lurbinectedin in people with lung cancer. The primary outcome being measured is Number of Participants With Objective Response Rate Assessed by Blinded Independent Central Review.
Based on ClinicalTrials.gov records.
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
lurbinectedin, topotecan
injection, intravenous, oral (Oral Capsule)
Primary: Number of Participants With Objective Response Rate Assessed by Blinded Independent Central Review, Overall Survival
Secondary: Change from Baseline in The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30, Change from Baseline in The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 29 (EORTC QLQ-LC29), Disease Control Rate As Assessed by Blinded Independent Central Review and Investigator, Duration of Response As Assessed by Blinded Independent Central Review and Investigator, Number of Participants With Objective Response Rate Assessed by Investigator, Overall Number of Participants With Treatment-emergent Adverse Events Following I-DXd Monotherapy, Pharmacokinetic Parameter Area Under the Plasma Concentration-Time Curve for I-DXd, Total Anti-B7-H3 Antibody, and MAAA-1181a, Pharmacokinetic Parameter Maximum Concentration for I-DXd, Total Anti-B7-H3 Antibody, and MAAA-1181a
Oncology